Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P J Maddon

Showing results (31-40 of 36) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 36 results.
Nature|June 20, 1996
HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5T Dragic, V Litwin, G P Allaway, et al.
The Journal of Infectious Diseases|July 7, 2000
Single-dose safety, pharmacology, and antiviral activity of the human immunodeficiency virus (HIV) type 1 entry inhibitor PRO 542 in HIV-infected adultsJ M Jacobson, I Lowy, C V Fletcher, et al.
Nature Medicine|January 14, 1998
AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptorG A Donzella, D Schols, S W Lin, et al.
Journal of Virology|January 7, 1998
Amino-terminal substitutions in the CCR5 coreceptor impair gp120 binding and human immunodeficiency virus type 1 entryT Dragic, A Trkola, S W Lin, et al.
Journal of Virology|April 10, 1999
Differential inhibition of human immunodeficiency virus type 1 fusion, gp120 binding, and CC-chemokine activity by monoclonal antibodies to CCR5W C Olson, G E Rabut, K A Nagashima, et al.
The Journal of Infectious Diseases|November 9, 2000
Recombinant CD4-IgG2 in human immunodeficiency virus type 1-infected children: phase 1/2 study. The Pediatric AIDS Clinical Trials Group Protocol 351 Study TeamW T Shearer, R J Israel, S Starr, et al.
Pageof 4

Showing results (31-40 of 36) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 36 results.
Nature|June 20, 1996
HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5T Dragic, V Litwin, G P Allaway, et al.
The Journal of Infectious Diseases|July 7, 2000
Single-dose safety, pharmacology, and antiviral activity of the human immunodeficiency virus (HIV) type 1 entry inhibitor PRO 542 in HIV-infected adultsJ M Jacobson, I Lowy, C V Fletcher, et al.
Nature Medicine|January 14, 1998
AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptorG A Donzella, D Schols, S W Lin, et al.
Journal of Virology|January 7, 1998
Amino-terminal substitutions in the CCR5 coreceptor impair gp120 binding and human immunodeficiency virus type 1 entryT Dragic, A Trkola, S W Lin, et al.
Journal of Virology|April 10, 1999
Differential inhibition of human immunodeficiency virus type 1 fusion, gp120 binding, and CC-chemokine activity by monoclonal antibodies to CCR5W C Olson, G E Rabut, K A Nagashima, et al.
The Journal of Infectious Diseases|November 9, 2000
Recombinant CD4-IgG2 in human immunodeficiency virus type 1-infected children: phase 1/2 study. The Pediatric AIDS Clinical Trials Group Protocol 351 Study TeamW T Shearer, R J Israel, S Starr, et al.
Pageof 4